Life Sciences Lifeline - Expanded TRIPS Waivers: What You Need to Know

Intellectual property protections for COVID-19-related diagnostics and therapeutics may soon be waived if the U.S. signs on to an agreement to expand access through the World Trade Organization.

Already in effect for COVID-19 vaccines, this policy, known as Trade-Related Aspects of Intellectual Property or TRIPS, has implications for manufacturers and investors beyond just COVID-19 targeted products.

Please join us as  speakers from trade bodies and affected companies break down the implications this policy could have for companies of all sizes.

Questions? Email Blakelee Kortz or call 317-231-7316.